oung and middle-aged patients with colon cancer are nearly two to eight times more likely to receive postoperative chemotherapy than older patients, yet there seems to be no added survival benefits for these patients, according to a study published today in JAMA Surgery by researchers at the Uniformed Services University of the Health Sciences (USU). Colorectal cancer is the third ...

Danish researchers from Aarhus University Hospital and Aarhus University are behind a possible breakthrough in the treatment of colorectal cancer. Annually about 2000 Danish patients with colorectal cancer are treated with chemotherapy. Today, a range of different chemotherapeutic regimens are available. However, deciding which regimen to use is not easy. Unfortunately, it is currently impossible to predict which regimen will ...

Researchers and physicians have grappled with the role of “adjuvant,” or post-surgery, chemotherapy for patients with early-stage colon cancer, even for cancers considered high risk. Now researchers from the University of Illinois at Chicago have found an association between the use of adjuvant chemotherapy in stage 2 colon cancer and improved survival — regardless of a patient’s age or risk, ...

Scientists at the Johns Hopkins Kimmel Cancer Center and University of Melbourne report they have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer. The DNA-based test, described in ...